A phase II study of high-dose cimetidine and the combination 5- fluorouracil, interferon alpha-2A, and leucovorin in advanced renal cell adenocarcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 5, 1998, Pages 475-478

  Creagan, Edward T ^a   Veeder, Michael H ^b   Suman, Vera J ^a   Burch, Patrick A ^a   Maples, William J ^a   Schaefer, Paul L ^c   Pfeifle, Delano M ^d   Dalton, Robert J ^e   Hatfield, Alan K ^f   Poon, Michael A ^g  

^a MAYO CLINIC   (United States)

^b Illinois Oncol Res Assoc CCOP   (United States)

^c Toledo Comm Clin Oncology Program   (United States)

^d Quain and Ramstad Clinic   (United States)

^e Duluth Community Clinical Oncology Program   (United States)

^f Carle Cancer Center CCOP   (United States)

^g Allan Blair Cancer Centre   (Canada)

Author keywords

Interferon; Renal cell cancer

Indexed keywords

CIMETIDINE; FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; RECOMBINANT ALPHA2A INTERFERON;

ADVANCED CANCER; AGED; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LETHARGY; MALE; MYALGIA; PHASE 2 CLINICAL TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CIMETIDINE; FEMALE; FLUOROURACIL; HISTAMINE H2 ANTAGONISTS; HUMANS; INTERFERON ALFA-2A; KIDNEY NEOPLASMS; LEUCOVORIN; MALE; MIDDLE AGED; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 0031756001     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199810000-00011     Document Type: Article

References (9)

1. Harris DT. Hormonal therapy and chemotherapy of renal cell carcinoma. J Clin Oncol 1990;8:1504-13.
2. Creagan ET, Buckner JC, Hahn RG, Richardson RL, Schaid DJ, Kovach JS. An evaluation of recombinant leukocyte A interferon with aspirin in patients with metastatic renal cell cancer. Cancer 1988;61:1787-91.
3. van Haelst-Pisani CM, Pisani RJ, Kovach JS. Cancer immuno-therapy: current status of treatment with interleukin-2 and lymphokine-activated killer cells. Mayo Clin Proc 1989;64:451-65.
4. Gifford RRM, Hatfield SM, Schmidtke JR. Cimetidine-induced augmentation of human lymphocyte blastogenesis by mitogen, bacterial antigen, and alloantigen. Transplantation 1980; 29:143-8.
5. Borgstrom S, von Eyben FE, Flodgren P, et al. Human leukocyte interferon and cimetidine for metastatic melanoma. N Engl J Med 1982;307:1080-1.
6. Morton RF, Creagan ET, Cullinan SA, Mailliard JA, Ebbert L, Veeder MH, Chang M. Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-Laspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma. J Clin Oncol Vol 5 1987;7:1078-82.
7. Kyle G, Wooley P, Kumar S, et al. Antiproliferative effects of human interferon in combination with radiation and chemotherapeutic drugs in five human cell lines [Abstract]. Proceedings of the American Association for Cancer Research 1985;26:327.
8. Wadler S, Lyver A, Goldman M, et al. Therapy with 5-fluorouracil and recombinant alpha-2a-interferon in refractory GI malignancies [Abstract]. Proceedings of the American Society of Clinical Oncology 1989;8:49.
9. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;10:1407-18.